Survivin: A molecular biomarker in cancer.

Abstract

Survivin, a member of the inhibitor of apoptosis (IAP) protein family that inhibits caspases and blocks cell death, is highly expressed in most cancers and is associated with a poor clinical outcome. Survivin has consistently been identified by molecular profiling analysis to be associated with high tumour grade cancers, different disease survival and recurrence. Polymorphisms in the survivin gene are emerging as powerful tools to study the biology of the disease and have the potential to be used in disease prognosis and diagnosis. The survivin gene polymorphisms have also been reported to influence tumour aggressiveness as well as survival of cancer patients. The differential expression of survivin in cancer cells compared to normal tissues and its role as a nodal protein in a number of cellular pathways make it a high target for different therapeutics. This review discusses the complex circuitry of survivin in human cancers and gene variants of survivin, and highlights novel therapy that targets this important protein.

• Authors: Praveen Kumar Jaiswal, Apul Goel, R D Mittal
• Journal: The Indian journal of medical research (Indian J Med Res) Vol. 141 Issue 4 Pg. 389-97 (Apr 2015) ISSN: 0971-5916 [Print] India
• PMID: 26112839 (Publication Type: Journal Article, Review)

Chemical References

• BIRC5 protein, human
• Biomarkers, Tumor
• Inhibitor of Apoptosis Proteins
• Survivin

Topics

• Apoptosis (genetics)
• Biomarkers, Tumor (genetics)
• Gene Expression Regulation, Neoplastic
• Humans
• Inhibitor of Apoptosis Proteins (chemistry, genetics)
• Molecular Targeted Therapy
• Neoplasms (classification, genetics, therapy)
• Polymorphism, Single Nucleotide
• Survivin